Hepatitis C Resources

 

1. Testimonial:

October 1, 2007

 To All At Enercel,

 I want to let you know how I’ve been getting along.

As you know, I’ve been fighting a few ailments.  Hep. C, Cirrhosis and Liver Cancer, which was also starting on my right lung.

 I went from 185 lbs. down to 135 lbs.  My Hep. C viral load was over 13,000,000.

 Some of the things I did to keep me alive, or I should say, to just keep my head above water were many intestinal cleanses, coffee enemas, (which were amazing), chelation, blood treatments like peroxide and ultra-violet light therapy.

 I knew in my heart my faith was very strong, that something was going to come along, as all things happen for me. 

 I met a lady in a Vitamin Store, her name was Renee.  She had just had one of several operations for cancer and to address post-radiation damage to her intestines at the time.  She was very weak, so I helped by watching over her for a week, before her family picked her up to take her to Sarasota as she recouped from this ordeal.

 During her long-term recuperation, she met with the C.E.O. of World Health, who after speaking with her decided to hire her for the Information Office.  During this time, she called me to say she was improving and that the cancer pallor was going away through the use of the product ENERCEL.

 Her integrity was so high, I didn’t hesitate to order some for myself, as I was desperate.

 I received the Plus I.M., Max, Mist and Forte.  My body is very sensitive to everything, and upon my first injection, I felt a wave of wellness all over my body.  It was fantastic!  The Mist gave me a similar sensation, while the Forte gave me back an appetite and energy.  The Max is a great way to start the day.  It seemed to get my circulation going.

 A Bio-Chemist/Geneticist re-checked my blood after about a year or of so using ENERCEL and my Hep. C viral load was under 500,000 from the previous time at 13,000,000.   She also stated my cirrhosis was gone and the cancer was cleared. 

 I’ve talked with a lot of people about ENERCEL.  Most of them ask if the treatment is covered by insurance and I say it isn’t. 

 I am 57  years old and have put my attention to beginning my dream of being a singer/entertainer.

 Thank you all at ENERCEL, and especially David Christner, for offering something that can turn bad health around!  Thank You!  Thank You!  Thank You!  YOU SAVED MY LIFE!

 I am more than happy to share my experience with anyone.  They may call: (786) 294-5479.

 Ron Ross

 

2. Study:

In the near future, World Health Advanced Technologies will be conducting a placebo-controlled study in conjunction with the Pasteur Institute in St. Petersburg Russia:

A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF ENERCEL® FOR BOTH TREATMENT NAÏVE AND PREVIOUSLY TREATED PATIENTS WITH CHRONIC HEPATITIS C INFECTION

OVERVIEW:

This is a double-blind, placebo-controlled, crossover trial of a homeopathic formulation, Enercel®, which is to be administered IV, IM and orally in patients with chronic Hepatitis C (HCV) infection that have an initial viral load ≥ 400,000 IU/ml. Eighty subjects will be enrolled into group A or group B-- forty into each group. Group A will receive blinded Enercel® for 3 months followed by placebo for 3 months and Group B will receive placebo for 3 months followed by blinded Enercel® for 3 months. Either treatment-naïve or previously treated patients with standard therapy including interferon alone or with ribavirin will be allowed into the trial. Statistical analysis will be applied to determine a primary endpoint of decreased viral load over time, and a secondary endpoint of comparative responses between treatment-naïve and treatment-experienced patients will be evaluated.

The study subjects will be voluntary, adult, participants who meet criteria for chronic HCV infection. Prior treatment with interferon alone or with ribavirin is permissible, but there is a 1 month wash-out period prior to enrollment. Newly-diagnosed and/or treatment naïve patients will also be enrolled. Study participants will each receive a standard Enercel® treatment protocol while on active treatment. The study period will be 6 months.

Enercel® or placebo will be given on the following schedule: 50cc IV daily for 10 days followed by IM 3cc daily for the duration of the study. In addition, Enercel® Max and Forte (or matching placebo) will be given 20 drops SL bid for the entire study. The participants will be monitored monthly or as clinically indicated.

Enercel® is a homeopathic formulation that has been used safely and successfully in multiple chronic viral infections. It appears to act primarily through enhancement of membrane potentials and alternate energy (ACE) pathways. It has been shown to increase Natural Killer (NK) cell function, a process that may be important in limiting persistent viral infections. It has demonstrated antiviral effect in animals. Case reports have demonstrated significant drops in hepatitis C viral load and improvement in clinical status for HCV patients treated with Enercel. Doses up to 50cc IV bid have been used without side-effects or toxicity.

A history of standard medical treatment consists of interferon alone or in combination with ribavirin.

3. Rationale for clinical study:

Hepatitis C infection affects nearly 200 million people worldwide, and the virus infects 3-4 million more people per year. It is currently a leading cause of cirrhosis, a common cause of hepatocellular carcinoma, and as a result of these conditions it is a leading reason for liver transplantation worldwide. The majority of patients with chronic hepatitis C will not clear it without treatment. HCV infections are common and widespread and result in significant morbidity and mortality; thus, effective treatment strategies are warranted.

Standard treatment with pegylated interferon and ribavirin usually results in significant side-effects and toxicity. Treated patients may qualify for temporary disability in some cases. A substantial proportion of patients will experience a panoply of side effects ranging from a 'flu-like' syndrome (the most common, experienced for a few days after the weekly injection of interferon) to severe adverse events including anemia, cardiovascular events and psychiatric problems such as suicide or suicidal ideation. The latter are exacerbated by the general physiological stress experienced by the patient during treatment. Thus, effective treatment with less or even no toxicity would be a significant advance in chronic HCV infections.

The average lifetime cost for hepatitis C, in the absence of liver transplant, has been estimated to be about $100,000 for individual patients. Assuming that 80% of the 4.5 million Americans believed to be infected develop chronic liver disease, the total lifetime cost for this group will be a staggering $360 billion in today's dollars. Assuming an estimated survival of 40 years, the annual health care costs for the affected U.S. population with chronic hepatitis C may be as high as $9 billion. Treatment with interferon and ribavirin over 48 weeks, including the cost of monitoring, can exceed $40,000. An effective, less-costly alternative with lower side-effects and toxicity (reducing costs of monitoring and treatment of adverse events) would significantly reduce the cost of treatment to society and the individual patient.

Genotypes 1a, 1b, 2a and 3a are most common in Russia, with an overall expected cure rate on interferon and ribavirin of about 50-60%. Treatment of cases with genotypes 1a and 1b are especially problematic, and regimens of up to 48 weeks or more are indicated. Given the potential seriousness of HCV infections, treatment strategies with higher cure rates are warranted.

The Hepatitis C virus demonstrates a vigorous propensity for chronic infection and evasion of the immune system. Several reasons have been proposed for this: the highly glycosylated nature of the viral envelope may protect it against antibody-mediated neutralization; the envelope may have evolved a structure (namely the putative E2 HVR-1 polypeptide loop) that allows it to decoy antibodies and to protect otherwise vulnerable, conserved receptor-binding ligands from antibody attack and the virus may regulate replication to a level that is too low to disrupt cellular homeostasis and that generates only meager amounts of viral antigens. Innate and adaptive immune mechanisms appear to be important in limiting HCV infections including antibody-mediated defenses, Cytotoxic Lymphocytes (CTL’s) and Natural Killer (NK) cells. As host and virus factors may result in suppressed immune function, treatments that enhance immunity may be of benefit.

Enercel® has proven to significantly enhance both innate (especially NK cells) and antigen-specific immune responses. Enercel® improves immune function in immunocompromised individuals such as HIV and cancer patients—this may be important in HCV-infected persons who may be functionally immune-suppressed due to host and virus effect.

Enercel® has been shown in multiple case studies and in vitro, animal and clinical trials to be free of side effects or toxicity. It could be of great benefit over interferon and ribavirin, which cause many adverse events that are even lethal in rare cases, if proven to be as or more effective in treating HCV infections. Furthermore, Enercel would cost less and require less costly monitoring.

The use of Enercel® could prove to be beneficial for chronic Hepatitis C infections for several reasons:

Enercel® has been proven to have significant broad-spectrum antiviral affect in case-studies, in vitro, animal and human trials

Enercel® improves immune system function

Enercel® is cost-effective

Enercel® has no toxicity or side-effects

Enercel® may reduce side-effects and toxicity from interferon and ribavirin

Patients with more treatment-resistant genotypes may still respond to Enercel®

Enercel® may provide a therapeutic option for those who failed or could not tolerate standard medical therapy with interferon and ribavirin

 

4. House of Grace Clinic: [healyourselfwithoutdrugs.com]

Dr. CJ Goodman will discuss with you the option of using Enercel in a comprehensive complementary medical approach to Hepatitis C.

Dr. CJ Goodman

1525 East Park Place; Ste. 1100

Stone Mountain, GA  30087               

404-949-7725 or 678-558-6767

 

References

  1. Caruntu FA, Benea L (2006). "Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment". Journal of Gastrointestinal and Liver Diseases : JGLD 15 (3): 249–56.
  2. Kamal SM (2008). "Acute hepatitis C: a systematic review". The American Journal of Gastroenterology 103 (5): 1283–97;
  3. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL (1999). "Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection". Hepatology 29 (3): 908–14.  
  4. Cox AL, Netski DM, Mosbruger T, et al. (2005). "Prospective evaluation of community-acquired acute-phase hepatitis C virus infection". Clin. Infect. Dis. 40 (7): 951–8.
  5. "NIH Consensus Development Conference on Management of Hepatitis C: 2002". http://consensus.nih.gov/2002/2002HepatitisC2002116main.htm.
  6. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP (2001). "Treatment of acute hepatitis C with interferon alfa-2b". New England Journal of Medicine 345 (20): 1452–1457.
  7. NIH Consensus Statement on Management of Hepatitis C. (2002) NIH Consens. State. Sci. Statements 19(3):1-46.: 2002
  8. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P, Thibault V,Benhamou Y, Moussalli J, Ratziu V, Poynard T (2006). "A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C". Clin Chem 52 (10): 1887–96.
  9. Halfon P, Munteanu M, Poynard T (2008). "FibroTest-ActiTest as a non-invasive marker of liver fibrosis". Gastroenterol Clin Biol 32 (6): 22–39.
  10. Pascual M, Perrin L, Giostra E, Schifferli J (1990). "Hepatitis C virus in patients with cryoglobulinemia type II.". J Infect Dis 162 (2): 569–70.
  11. Johnson R, Gretch D, Yamabe H, Hart J, Bacchi C, Hartwell P, Couser W, Corey L, Wener M, Alpers C (1993). "Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.". N Engl J Med 328 (7): 465–70
  12. Zignego Al, Ferri C; ) Commission On Extrahepatic Manifestations Of HCV Infection, for the Italian Association of the Study of Liver (A.I.S.F (2006). "Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach". Dig Liver Dis. 39 (1): E-publication.
  13. "HCV Prevalence in Selected Groups of Adults by History of Injection Drug Use". http://www.cdc.gov/ncidod/diseases/hepatitis/partners/nvhpc_2005/Thursday/PL4Alter.ppt
  14. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (April 1989). "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome". Science 244 (4902): 359–62.
  15. Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G (2006). "A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection". J. Viral Hepat. 13 (11): 775–82.
  16. Vandelli C, Renzo F, Romanò L, et al. (2004). "Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study". Am J Gastroenterol. 99 (5): 855–9.
  17. Marcellin, P (1999). "Hepatitis C: the clinical spectrum of the disease". Journal of Hepatology 31 Suppl 1: 9–16. PMID 10622554.  
  18. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M (2007). "The way forward in HCV treatment—finding the right path". Nat Rev Drug Discov 6 (12): 991–1000.
  19. Watanabe H, Saito T, Shinzawa H, Okumoto K, Hattori E, Adachi T, Takeda T, Sugahara K, Ito J, Saito K, Togashi H, Suzuki R, Hayashi M, Miyamura T, Matsuura Y, Kawata S (2003). "Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study". J Med Virol 71 (1): 56–61.
  20. "Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials.". Hepatology (Baltimore, Md.). 2009. 
  21. Shiffman ML, Suter F, Bacon BR, et al. (2007). "Peginterferon Alfa-2a and Ribavirin for 16 or 24 weeks in HCV genotype 2 or 3". N Engl J Med 357 (2): 124–34.
  22.  Scott J, McMahon B, Bruden D, Sullivan D, Homan C, Christensen C, Gretch D (2006). "High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives". Clin Infect Dis 42 (7): 945–52.
  23. Castillo, I; Rodríguez-Iñigo, E; López-Alcorocho, JM; Pardo, M; Bartolomé, J; Carreño, V (2006). "Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment". Clin Infect Dis 43 (10): 1277–83.
  24. Fung J, Lai C-L, Hung I, et al. (2008). "Chronic Hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin". J Infect Dis 198 (6): 808–12. 
  25. Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature 461 (7262): 399–401.
  26.  Ruiz J, Molitor F, Plagenhoef J (2002). "Trends in hepatitis C and HIV infection among inmates entering prisons in California, 1994 versus 1999.". AIDS 16 (16): 2236–8.
  27. Thomas DL, Thio CL, Martin MP, et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature 461 (7265): 798–801.
  28. Enomoto N, Maekawa S (2010) HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 53(1):66-69
  29. Mast E (2004). "Mother-to-infant hepatitis C virus transmission and breastfeeding." Adv Exp Med Biol 554: 211–6.
  30. NCCAM. Hepatitis C and Complementary and Alternative Medicine: 2003 Update. May 2004.
  31. Campbell J, Hagan H, Latka M, Garfein R, Golub E, Coady M, Thomas D, Strathdee S (2006). "High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities." Drug Alcohol Depend 81 (3): 259–65.
  32. McGovern B, Wurcel A, Kim A, Schulze zur Wiesch J, Bica I, Zaman M, Timm J, Walker B, Lauer G (2006). "Acute hepatitis C virus infection in incarcerated injection drug users.". Clin Infect Dis 42 (12): 1663–70.
  33. Chapter 4 - Hepatitis, Viral, Type C - Yellow Book, CDC Health Information for International Travel 2008
  34. Frank C, Mohamed M, Strickland G, Lavanchy D, Arthur R, Magder L, El Khoby T, Abdel-Wahab Y, Aly Ohn E, Anwar W, Sallam I (2000). "The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt.". Lancet 355 (9207): 887–91.
  35. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens R, Calleja J, Forns X, Erhardt A, Crönlein J, Chaves R, Yong C, Nehmiz G, Steinmann G (2004). "Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients." Gastroenterology 127 (5): 1347–55.
  36. Lamarre D, Anderson P, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron D, Cartier M, Cordingley M, Faucher A, Goudreau N, Kawai S, Kukolj G, Lagacé L, LaPlante S, Narjes H, Poupart M, Rancourt J, Sentjens R, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos Y, Weldon S, Yong C, Llinàs-Brunet M (2003). "An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.". Nature 426 (6963): 186–9.
  37. Poo, Jorge L.; Francisco Sánchez Ávila; David Kershenobich; Xochitl García Samper; Rocío Torres-Ibarra; Julieta Góngora; Carlos Cano; Miguel Parada;1 Misael Uribe (2008). "Efficacy of triple therapy with thymalfasin, peginterferon α-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders" (PDF). Annals of Hepatology.
  38. 40. Maynard M, Pradat P, Bailly F, Rozier F, Nemoz C, Si Ahmed S, Adeleine P, Trépo C (2006). "Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies." J Hepatol 44 (3): 484–90.  
  39. McCaffrey A, Meuse L, Karimi M, Contag C, Kay M (2003). "A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice." Hepatology 38 (2): 503–8
  40. See DM, Tilles JG, Bertacchini C. “Immunomodulatory Effects of a Homeopathic Agent.” J Nat Med 1997.
  41. Izaguirre RR, Guzmán, MR, Fuentes, RC, Mena CE, Peñate E. Effect Of A New Alternative Medicine In Acute Diarrheas, Including Those Caused By Rotavirus, In Children Less Than 5 Years Of Age Consulting At The Emergency Ward Of B. Bloom Hospital In San Salvador, Between August 2003 And April 2004.” Abstract.
    42.
  42. Zhang H, Hanecak R, Brown-Driver V, Azad R, Conklin B, Fox M, Anderson K (1 February 1999). "Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant.". Antimicrob Agents Chemother 43 (2): 347–53.